Cimetidine
- cimetidine
- 51481-61-9
- Tagamet
- Ulcedin
- Acinil
- Create:2004-09-16
- Modify:2025-01-18
- Altramet
- Biomet
- Biomet400
- Cimetidine
- Cimetidine HCl
- Cimetidine Hydrochloride
- Eureceptor
- HCl, Cimetidine
- Histodil
- Hydrochloride, Cimetidine
- N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine
- SK and F 92334
- SK and F-92334
- SK and F92334
- SKF 92334
- SKF-92334
- SKF92334
- Tagamet
- cimetidine
- 51481-61-9
- Tagamet
- Ulcedin
- Acinil
- Dyspamet
- Eureceptor
- Gastromet
- Tametin
- Ulcimet
- Cimal
- Ulcomedina
- Cimetag
- Ulcedine
- Tratul
- Acibilin
- Cimetidina
- Cimetum
- Edalene
- Ulcomet
- Ulhys
- Tagamet Hb
- SKF-92334
- Tagamet Hb 200
- Cimetidinum
- Metracin
- Valmagen
- Brumetidina
- Gastrobitan
- Ulcestop
- Evicer
- 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
- Stomedine
- Aciloc
- N-Cyano-N'-methyl-N''-[2-[[(4-methyl-1H-imidazol-5-yl)methyl]thio]ethyl]guanidine
- SKF 92334
- Cimetidinum [INN-Latin]
- Cimetidina [INN-Spanish]
- DRG-0150
- 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine
- CCRIS 3247
- CHEBI:3699
- Topcare heartburn relief
- NSC-335308
- HSDB 3917
- 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine
- FPF 1002
- EINECS 257-232-2
- MFCD00133296
- UNII-80061L1WGD
- N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine
- DTXSID4020329
- 80061L1WGD
- CHEMBL30
- NSC 335308
- Brumetadina
- DTXCID40329
- 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
- Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-
- MLS000069791
- 2984-61-4
- 76181-71-0
- Ulcofalk
- Peptol
- 51481-61-9 (free)
- NSC335308
- Guanidine, N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-
- Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio) ethyl)-
- Guanidine, N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-
- Guanidine, N-cyano-N'-Methyl-N''-[2-[[(5-Methyl-1H-iMidazol-4-yl)Methyl]thio]ethyl]-, (Z)-
- N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
- NSC 757428
- 943920-67-0
- Cimetidine [USAN:USP:INN:BAN:JAN]
- NCGC00015240-06
- SMR000038895
- Cimetidine 100 microg/mL in Acetonitrile
- CIMETIDINE (IARC)
- CIMETIDINE [IARC]
- Cimetidinum (INN-Latin)
- Cimetidina (INN-Spanish)
- CIMETIDINE (MART.)
- CIMETIDINE [MART.]
- (Z)-3-cyano-1-methyl-2-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
- 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
- CIMETIDINE (USP-RS)
- CIMETIDINE [USP-RS]
- N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
- CIMETIDINE (EP MONOGRAPH)
- CIMETIDINE [EP MONOGRAPH]
- 4H-Dithieno[3,2-b :2',3'-d ]pyrrole, 4-(1-octylnonyl)-
- CIMETIDINE (USP MONOGRAPH)
- CIMETIDINE [USP MONOGRAPH]
- Cimetidine (USAN:USP:INN:BAN:JAN)
- (Z)-N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
- 2-CYANO-1-METHYL-3-(2-(((5-METHYLIMIDAZOL-4-YL)METHYL)THIO)ETHYL)-GUANIDINE
- Guanidine, N''-cyano-N-methyl-N'-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-
- Tagamet (TN)
- Equaline acid reducer
- SR-01000075260
- SR-05000001434
- cemitidine
- metidine
- Cimetidin
- Equate Cimetidine
- 1-cyano-2-methyl-3-(2-((5-methyl-1H-imidazol-4-yl)methylthio)ethyl)guanidine
- 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine
- 2-cyano-1-methyl-3-(2-(((5-methyl-1H-imidazol-4-yl)methyl)sulfanyl)ethyl)guanidine
- 2-Cyano-1-methyl-3-(2-((5-methyl-1H-imidazol-4-yl)methylsulfanyl)ethyl)guanidine
- 2-cyano-1-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
- Cimetidine,(S)
- N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine
- N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)sulfanyl)ethyl)guanidine
- Prestwick_65
- cimetidineacid reducer
- TRATUE
- N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine
- Cimetidine (Tagamet)
- Cimetidine (Standard)
- Spectrum_000495
- Tocris-0902
- CIMETIDINE [MI]
- Opera_ID_314
- SunMark heartburn relief
- CIMETIDINE [INN]
- CIMETIDINE [JAN]
- Prestwick3_000026
- Spectrum2_000782
- Spectrum3_001389
- Spectrum4_000812
- Spectrum5_001541
- CIMETIDINE [HSDB]
- CIMETIDINE [USAN]
- Lopac-C-4522
- CIMETIDINE [VANDF]
- UPCMLD-DP029
- 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine
- C 4522
- SCHEMBL1093
- SCHEMBL1094
- SKF-92334; Tagamet
- Good Sense Heartburn Relief
- CIMETIDINE [WHO-DD]
- CIMETIDINE [WHO-IP]
- Lopac0_000293
- BSPBio_000091
- BSPBio_002978
- KBioGR_001323
- KBioSS_000975
- US9138393, Cimetidine
- US9144538, Cimetidine
- MLS001148596
- MLS002153265
- MLS002154178
- DivK1c_000166
- SPECTRUM1500684
- SPBio_000884
- BPBio1_000101
- Cimetidine (JP18/USP/INN)
- GTPL1231
- CIMETIDINE [ORANGE BOOK]
- SCHEMBL11282982
- UPCMLD-DP029:001
- BDBM22889
- Cimetidine for system suitability
- HMS500I08
- KBio1_000166
- KBio2_000975
- KBio2_003543
- KBio2_006111
- KBio3_002198
- A02BA01
- Cimetidine for peak identification
- NINDS_000166
- BDBM181119
- HMS1921C14
- HMS2089O03
- HMS2092I14
- HMS2095E13
- HMS2232F16
- HMS3259M15
- HMS3260L08
- HMS3267A03
- HMS3369L10
- HMS3414I17
- HMS3651E21
- HMS3678I17
- HMS3712E13
- HMS3750I05
- HMS3884I12
- Pharmakon1600-01500684
- Cimetidine 1.0 mg/ml in Methanol
- CIMETIDINUM [WHO-IP LATIN]
- EX-A1088
- SunMark heartburn reliefacid reducer
- Tox21_110106
- Tox21_201160
- Tox21_500293
- BDBM50103595
- BDBM50403559
- CCG-40160
- HY-14289R
- NSC757428
- s1845
- STK528249
- 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine
- AKOS005460997
- AKOS015900557
- AKOS015951369
- AKOS016003398
- AKOS016340377
- AKOS026749950
- AKOS032949548
- AKOS040824773
- Tox21_110106_1
- AB03708
- AC-8100
- CCG-204388
- CCG-220026
- CCG-221597
- DB00501
- KS-5087
- LP00293
- NC00501
- NSC-757428
- SDCCGSBI-0050281.P005
- 1-cyano-2-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
- Good Neighbor Pharmacy Heartburn Relief
- IDI1_000166
- N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine
- N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine
- NCGC00015240-01
- NCGC00015240-02
- NCGC00015240-03
- NCGC00015240-04
- NCGC00015240-05
- NCGC00015240-07
- NCGC00024859-01
- NCGC00024859-02
- NCGC00024859-03
- NCGC00024859-04
- NCGC00024859-05
- NCGC00091439-01
- NCGC00091439-02
- NCGC00091439-03
- NCGC00091439-04
- NCGC00091439-05
- NCGC00091439-07
- NCGC00091439-10
- NCGC00185989-01
- NCGC00188961-01
- NCGC00258712-01
- NCGC00260978-01
- 270574-63-5
- HY-14289
- NCI60_002936
- SY057952
- SBI-0050281.P004
- DB-051971
- EU-0100293
- NS00008665
- SW196380-2
- EN300-73705
- C06952
- D00295
- F16651
- AB00052157-03
- AB00052157_04
- AB00052157_05
- A828616
- EN300-27121291
- EN300-27121293
- L000186
- L003827
- L013434
- Q409492
- SR-05000001750
- Q-200855
- Q-200856
- SR-01000075260-1
- SR-01000075260-3
- SR-05000001434-1
- SR-05000001434-2
- SR-05000001750-1
- BRD-K18618618-001-01-6
- BRD-K34157611-001-04-6
- BRD-K34157611-001-07-9
- BRD-K34157611-001-14-5
- BRD-K34157611-001-15-2
- BRD-K34157611-001-16-0
- Z1162463430
- Cimetidine, European Pharmacopoeia (EP) Reference Standard
- Cimetidine, United States Pharmacopeia (USP) Reference Standard
- 1-Cyan-2-methyl-3-(2-{[(5-methylimidazol-4-yl)methyl]thio}ethyl)guanidin
- Cimetidine, Pharmaceutical Secondary Standard; Certified Reference Material
- N"-cyano-N-methyl-N'-[2-(5-methylimidazol-4-ylmethylthio)ethyl]-guanidine
- N"-cyano-N-methyl-N'-[2-(5-methylimidazol-4-ylmethylthio)ethyl]guanidine
- N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)methylthio)ethyl]guanidine
- N-cyano-N'-methyl-N"-[2-((5-methyl-4-imidazolyl)methylthio)ethyl]guanidine
- N-cyano-N'-methyl-N"-[2-(5-methyl-4-imidazolylmethylthio)ethyl]guanidine
- (E)-2-cyano-1-methyl-3-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine
- (Z)-1-cyano-2-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
- 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-benzenesulfonamide(Cimetidine)
- 2-Methyl-8-phenethyl-imidazo[1,2-a]pyridine-3-carboxylic acid methyl ester(cimetidine)
- 2-methylamino-2-[2-(4-methyl-1H-5-imidazolylmethylsulfanyl)ethylamino]-(E)-1-imino cyanide
- 3-cyano-2-methyl-1-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
- 4-(((2-(((cyanoamino)(methylamino)methylene)amino)ethyl)thio)methyl)-5-methyl-1H-imidazole
- Cimetidine for peak identification, European Pharmacopoeia (EP) Reference Standard
- Cimetidine for system suitability, European Pharmacopoeia (EP) Reference Standard
- Guanidine, N-cyano-N'-methyl-N''-[2-[[5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-
- N''-cyano-N-methyl-N'-(2-((5-methyl-1h-imidazol-4-yl)-methylthio)ethyl)guanidine
- N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
- N-cyano-N'-methyl-N"- [2-((5-methyl-4-imidazolyl)methylthio)ethyl]guanidine
- N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl) methylthio)ethyl]guanidine
- N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)- methylthio)ethyl]guanidine
- N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)-methylthio)ethyl]guanidine
- N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)methyl-thio)ethyl]guanidine
- N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)methylthio)ethyl) guanidine
- N-cyano-N'-methyl-N"-[2-((5-methyl-4-imidazolyl)methylthio)-ethyl]guanidine
- N-cyano-N'-methyl-N"-[2-((5-methyl-4-imidazolyl)methylthio)ethyl]-guanidine
- N-cyano-N'-methyl-N"-[2-{(5-methyl-1H-imidazol-4-yl)methylthio}ethyl]guanidine
- N-CYANO-N'-METHYL-N''-(2(((5-METHYL-1H-IMIDAZOL-4-YL)METHYL)THIO)ETHYL)
- N-Cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine #
- N-cyano-N'-methyl-N''-[2-[[(5-methylimidazol-4-yl]methyl]thio]ethyl)guanidine
- N-cyano-N'-methyl-N-"-[2-((4-methyl-5-imidazolyl)methylthio)ethyl]guanidine
- N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N"-cyanoguanidine
- N-methyl-N-[2-(5-methyl-1H-4-imidazolylmethylsulfanyl)ethyl]-1-cyanoiminomethanediamine
- N-methyl-N-[2-(5-methyl-1H-4-imidazolylmethylsulfanyl)ethyl]imino(-N-cyano)methanediaminem
- N-tert-Butyl-N''''''''-[4-(1H-imidazol-4-yl)-phenyl]-formamidine(cimetidine)
- (Cimetidine) N-Methyl-N''''''''-[2-(5-methyl-1H-imidazol-4-ylmethylsulfanyl)-ethyl]-guanidine,cyanide
- (cimetidine) N-methyl-N-[2-(5-methyl-1H-4-imidazolylmethylsulfanyl)ethyl]cyanoiminomethanediamine
- (Cimetidine)N-methyl-N-[2-(5-methyl-1H-4-imidazolylmethylsulfanyl)ethyl]cyanomethyliminomethanediamine
- (E)-N''-CYANO-N-METHYL-N'-(2-{[(5-METHYL-1H-IMIDAZOL-4-YL)METHYL]SULFANYL}ETHYL)GUANIDINE
- ; N''''''''''''''''-cyano-N-methyl-N''''''''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine
- 2-methylamino-2-[2-(5-methyl-1H-4-imidazolylmethylsulfanyl)ethylamino]-(Z)-1-imino cyanide(cimetidine)
- N''''''''''''''''''''''''''''''''-cyano-N-methyl-N''''''''''''''''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
- N''''''''''''''''-cyano-N-methyl-N''''''''-({[(5-methyl-1H-imidazol-4-yl)methyl]thio}methyl)guanidine(cimetidine)
- N''''''''''''''''-cyano-N-methyl-N''''''''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]-lambda~4~-sulfanyl}ethyl)guanidine
- N''''''''''''''''-cyano-N-methyl-N''''''''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
- N''''''''''''''''-cyano-N-methyl-N''''''''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine (Cimetidine)
- N''''''''''''''''-cyano-N-methyl-N''''''''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine(cimetidine)
- N-Cyano-N''''''''-methyl-N''''''''''''''''-(2-(((5-methyl-1H-imidazol-4-yl) methyl)thio)ethyl)guanidine(Cimetidine)
- N-cyanomethyl-N''''''''-methyl-N''''''''''''''''-[2-(5-methyl-1H-imidazol-4-ylmethylsulfanyl)-ethyl]-guanidine ( Cimetidine)
- N-Methyl-N''''''''-[2-(5-methyl-1H-imidazol-4-ylmethylsulfanyl)-ethyl]-cyanoguanidine(cimetidine)
- N-Methyl-N''''''''-[2-(5-methyl-1H-imidazol-4-ylmethylsulfanyl)-ethyl]-N''''''''''''''''-Cyano-guanidine
- N-Methyl-N''''''''-[2-(5-methyl-1H-imidazol-4-ylmethylsulfanyl)-ethyl]-N''''''''''''''''-cyano-guanidine(Cimetidine)
- N-methyl-N''''''''-cyano-N''''''''''''''''-[2-(5-methyl-1H-imidazol-4-ylmethylsulfanyl)-ethyl]-guanidine
- N-methyl-N-[2-(5-methyl-1H-4-imidazolylmethylsulfanyl)ethyl]cyanoiminomethanediamine (cimetidine)
154.58 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
160.52 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
159.55 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
159.0697 100
117.048 63.98
95.0603 51.07
253.1228 13.93
172.0901 4.44
95.0603 100
159.0698 61.52
117.048 59.21
99.0664 19.88
103.0324 3.59
253.1227 999
159.0697 711
117.048 397
95.0602 142
211.1011 92
159.0697 999
117.048 639
95.0603 510
253.1228 139
172.0901 44
- Cimetidine Hydrochloride (has salt form)
- Cimetidine; ibuprofen; salicylic acid (component of)
- Cimetidine; lidocaine; salicylic acid (component of)
- Cytoplasm
- Membrane
Use (kg; approx.) in Germany (2009): >1000
Use (kg) in USA (2002): 39500
Consumption (g per capita; approx.) in Germany (2009): 0.0122
Consumption (g per capita) in the USA (2002): 0.14
Excretion rate: 0.75
Calculated removal (%): 22
H318 (39.1%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
H360 (57.2%): May damage fertility or the unborn child [Danger Reproductive toxicity]
H373 (25.4%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]
P203, P260, P264+P265, P280, P305+P354+P338, P317, P318, P319, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 138 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Reported as not meeting GHS hazard criteria per 1 of 138 reports by companies. For more detailed information, please visit ECHA C&L website.
There are 10 notifications provided by 137 of 138 reports by companies with hazard statement code(s).
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Eye Dam. 1 (39.1%)
Repr. 1B (57.2%)
STOT RE 2 (25.4%)
SYMPTOMS: Symptoms of exposure to this compound can include, dermatitis, hair growth, rash, pruritus, erythema annulare centrifugum; anorexia, gastritis, gastrointestinal changes, diarrhea, constipation, nausea, ulcer perforation upon withdrawal; hepatitis, jaundice, increases in serum creatinine and liver enzymes, changes in kidney tubules, interstitial nephritis and possible renal failure; hypotension, increased body temperature, sweating; muscle weakness and/or pain; endocrine changes, gynecomastia; leukopenia, agranulocytosis, thrombocytopenia; transient psychosis, confusion, disorientation, agitation, hallucinations, dizziness, somnolence, headache, fatigue, malaise; loss of libido and impotence.
ACUTE/CHRONIC HAZARDS: When heated to decomposition this compound emits very toxic fumes of NOx and SOx. (NTP, 1992)
EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.
SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.
INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should be used; if not available, use a level of protection greater than or equal to that advised under Protective Clothing.
INGESTION: DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital. (NTP, 1992)
SMALL SPILLS AND LEAKAGE: If you spill this chemical, FIRST REMOVE ALL SOURCES OF IGNITION. You should then dampen the solid spill material with 60-70% methanol, then transfer the dampened material to a suitable container. Use absorbent paper dampened with methanol to pick up any remaining material. Your contaminated clothing and absorbent paper should be sealed in a vapor-tight plastic bag for eventual disposal. Solvent-wash contaminated surfaces with 60-70% methanol followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.
STORAGE PRECAUTIONS: You should store this material under ambient conditions. (NTP, 1992)
Amines, Phosphines, and Pyridines
Sulfides, Organic
Nitriles
Chronic therapy with cimetidine has been associated with minor elevations in serum aminotransferase levels in 1% to 4% of patients, but similar rates were reported in placebo recipients. The ALT elevations were usually asymptomatic and transient and usually resolved even without dose modification. Several instances of clinically apparent liver injury have been reported in patients receiving cimetidine, but the time to onset and pattern of injury has varied greatly. Onset can be as short as a few days to as long as 7 months, and the serum enzyme pattern varies from hepatocellular to cholestatic, most cases having a “mixed” hepatocellular-cholestatic pattern of injury (Cases 1 and 2). The injury is rarely severe and resolves within 4 to 12 weeks of stopping cimetidine. Liver biopsy histology often shows prominent centrolobular necrosis. Immunoallergic features (rash, fever, eosinophilia) are uncommon, as is autoantibody formation.
Likelihood score: B (highly likely cause of clinically apparent liver injury).
M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007
M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
◉ Summary of Use during Lactation
Maternal cimetidine doses of 1000 to 1200 mg daily result in infant dosages that are much less than reported neonatal dosages of 5 to 10 mg/kg daily. Cimetidine would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months. However, because of its potential for causing hepatic enzyme inhibition, other drugs might be preferred. Cimetidine can increase serum prolactin and it has been used, but not validated, as a galactogogue.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Histamine H2-receptor blockade is known to stimulate prolactin secretion. In addition, cimetidine may have additional, nonspecific actions that stimulate prolactin secretion. Oral cimetidine doses of 400 mg 4 times daily increased serum prolactin by 50 to 112% in 6 patients. Cimetidine has caused dose-related gynecomastia and galactorrhea in men and nonnursing women. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
One clinician reported that she used cimetidine 200 or 300 mg 4 times daily to nursing mothers with a marginal or low milk supply. Subjective reports indicated an increase in milk supply.
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=AQIXAKUUQRKLND-UHFFFAOYSA-N
- Australian Industrial Chemicals Introduction Scheme (AICIS)Guanidine, N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-https://services.industrialchemicals.gov.au/search-assessments/
- CAMEO ChemicalsLICENSECAMEO Chemicals and all other CAMEO products are available at no charge to those organizations and individuals (recipients) responsible for the safe handling of chemicals. However, some of the chemical data itself is subject to the copyright restrictions of the companies or organizations that provided the data.https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=falseCAMEO Chemical Reactivity Classificationhttps://cameochemicals.noaa.gov/browse/react
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/
- ChemIDplusCimetidine [USAN:USP:INN:BAN:JAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0051481619ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useCimetidinehttps://www.drugbank.ca/drugs/DB00501
- DTP/NCILICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuse
- EPA DSSToxCompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-noticeCimetidine (EC: 257-232-2)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/37353
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Hazardous Substances Data Bank (HSDB)
- Human Metabolome Database (HMDB)LICENSEHMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.http://www.hmdb.ca/citingHMDB0014644_nmr_one_2428https://hmdb.ca/metabolites/HMDB0014644#spectra
- BindingDBLICENSEAll data curated by BindingDB staff are provided under the Creative Commons Attribution 3.0 License (https://creativecommons.org/licenses/by/3.0/us/).https://www.bindingdb.org/rwd/bind/info.jsp(Cimetidine) N-Methyl-N''''-[2-(5-methyl-1H-imidazol-4-ylmethylsulfanyl)-ethyl]-guanidine,cyanidehttps://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=22889
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- Comparative Toxicogenomics Database (CTD)LICENSEIt is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.http://ctdbase.org/about/legal.jsp
- Drug Gene Interaction database (DGIdb)LICENSEThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.http://www.dgidb.org/downloadsCIMETIDINEhttps://www.dgidb.org/drugs/rxcui:2541
- IUPHAR/BPS Guide to PHARMACOLOGYLICENSEThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)https://www.guidetopharmacology.org/about.jsp#licenseGuide to Pharmacology Target Classificationhttps://www.guidetopharmacology.org/targets.jsp
- Therapeutic Target Database (TTD)
- Toxin and Toxin Target Database (T3DB)LICENSET3DB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (T3DB) and the original publication.http://www.t3db.ca/downloadsCimetidinehttp://www.t3db.ca/toxins/T3D2810
- ChEBI
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Pharmacological Classificationhttps://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
- LiverTox
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licence
- CCSbaseCCSbase Classificationhttps://ccsbase.net/
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- Haz-Map, Information on Hazardous Chemicals and Occupational DiseasesLICENSECopyright (c) 2022 Haz-Map(R). All rights reserved. Unless otherwise indicated, all materials from Haz-Map are copyrighted by Haz-Map(R). No part of these materials, either text or image may be used for any purpose other than for personal use. Therefore, reproduction, modification, storage in a retrieval system or retransmission, in any form or by any means, electronic, mechanical or otherwise, for reasons other than personal use, is strictly prohibited without prior written permission.https://haz-map.com/AboutCimetidinehttps://haz-map.com/Agents/1319
- Crystallography Open Database (COD)LICENSEAll data in the COD and the database itself are dedicated to the public domain and licensed under the CC0 License. Users of the data should acknowledge the original authors of the structural data.https://creativecommons.org/publicdomain/zero/1.0/
- DailyMed
- Drug Induced Liver Injury Rank (DILIrank) DatasetLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Drugs and Lactation Database (LactMed)
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- EPA Chemical and Products Database (CPDat)EPA CPDat Classificationhttps://www.epa.gov/chemical-research/chemical-and-products-database-cpdat
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/CIMETIDINENORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- EU Clinical Trials Register
- FDA Orange BookLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- USGS Health-Based Screening Levels for Evaluating Water-Quality DataLICENSEhttps://www.usgs.gov/legal
- SpectraBase2-CYANO-1-METHYL-3-{2-{[(5-METHYLIMIDAZOL-4-YL)METHYL]THIO}ETHYL}GUANIDINEhttps://spectrabase.com/spectrum/AfKZbaHjBEH2-cyano-1-methyl-3-{2-{[(5-methylimidazol-4-yl)methyl]thio}ethyl}guanidinehttps://spectrabase.com/spectrum/69vaH11rliR2-CYANO-1-METHYL-3-{2-{[(5-METHYLIMIDAZOL-4-YL)METHYL]THIO}ETHYL}GUANIDINEhttps://spectrabase.com/spectrum/I2LNYyXfH3I2-CYANO-1-METHYL-3-{2-{[(5-METHYLIMIDAZOL-4-YL)METHYL]THIO}ETHYL}GUANIDINEhttps://spectrabase.com/spectrum/4X2qBKNqcyZ
- NIST Mass Spectrometry Data CenterLICENSEData covered by the Standard Reference Data Act of 1968 as amended.https://www.nist.gov/srd/public-lawCimetidinehttp://www.nist.gov/srd/nist1a.cfm
- International Agency for Research on Cancer (IARC)LICENSEMaterials made available by IARC/WHO enjoy copyright protection under the Berne Convention for the Protection of Literature and Artistic Works, under other international conventions, and under national laws on copyright and neighbouring rights. IARC exercises copyright over its Materials to make sure that they are used in accordance with the Agency's principles. All rights are reserved.https://publications.iarc.fr/Terms-Of-UseIARC Classificationhttps://www.iarc.fr/
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlTherapeutic category of drugs in Japanhttp://www.genome.jp/kegg-bin/get_htext?br08301.kegUSP drug classificationhttp://www.genome.jp/kegg-bin/get_htext?br08302.kegAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.kegDrugs listed in the Japanese Pharmacopoeiahttp://www.genome.jp/kegg-bin/get_htext?br08311.kegRisk category of Japanese OTC drugshttp://www.genome.jp/kegg-bin/get_htext?br08312.kegClassification of Japanese OTC drugshttp://www.genome.jp/kegg-bin/get_htext?br08313.keg
- MassBank Europe
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- Metabolomics Workbench
- Nature Chemical Biology
- NIPH Clinical Trials Search of Japan
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmlcimetidinehttps://rxnav.nlm.nih.gov/id/rxnorm/2541
- PharmGKBLICENSEPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).https://www.pharmgkb.org/page/policies
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/about
- RCSB Protein Data Bank (RCSB PDB)LICENSEData files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data.https://www.rcsb.org/pages/policies
- Springer Nature
- The Cambridge Structural Database
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/
- Wikidatacimetidinehttps://www.wikidata.org/wiki/Q409492
- WikipediaCimetidinehttps://en.wikipedia.org/wiki/Cimetidine
- Wiley
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlCytochrome P-450 CYP1A2 Inhibitorshttps://www.ncbi.nlm.nih.gov/mesh/68065609Histamine H2 Antagonistshttps://www.ncbi.nlm.nih.gov/mesh/68006635Anti-Ulcer Agentshttps://www.ncbi.nlm.nih.gov/mesh/68000897
- PubChem
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- EPA Substance Registry ServicesEPA SRS List Classificationhttps://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 403396820https://pubchem.ncbi.nlm.nih.gov/substance/403396820
- NCBI